与阿米卡星脂质体吸入混悬液相关的呼吸不良事件的临床管理：一项患者调查结果
Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey.
作者信息
Swenson Colin, Lapinel Nicole C, Ali Juzar
机构信息
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, Georgia, USA.
Section of Pulmonary/Critical Care Medicine & Allergy/Immunology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
出版信息
Open Forum Infect Dis. 2020 Mar 2;7(4):ofaa079. doi: 10.1093/ofid/ofaa079. eCollection 2020 Apr.
Abstract
Patients with complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.
摘要
在美国两家诊所接受阿米卡星脂质体吸入混悬液（ALIS）治疗的复杂肺部疾病患者接受了调查，以评估与ALIS相关的呼吸道不良事件的发生频率和处理情况。大多数受访者经历过这些事件，但通过医生指导的措施（如使用支气管扩张剂、口腔冲洗和/或临时调整剂量）进行处理后症状得到改善。
相似文献
1
Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey.与阿米卡星脂质体吸入混悬液相关的呼吸不良事件的临床管理：一项患者调查结果
Open Forum Infect Dis. 2020 Mar 2;7(4):ofaa079. doi: 10.1093/ofid/ofaa079. eCollection 2020 Apr.
2
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂（CONVERT）引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
3
Amikacin Liposome Inhalation Suspension for Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial.阿米卡星脂质体吸入混悬液治疗复杂肺部疾病：一项为期 12 个月的开放性标签扩展临床试验。
Ann Am Thorac Soc. 2021 Jul;18(7):1147-1157. doi: 10.1513/AnnalsATS.202008-925OC.
4
Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection.阿米卡星脂质体吸入混悬液治疗耐多药鸟分枝杆菌复合群肺部感染。
Expert Rev Respir Med. 2021 Jun;15(6):737-744. doi: 10.1080/17476348.2021.1875821. Epub 2021 May 26.
5
Amikacin Liposome Inhalation Suspension for Complex Lung Disease.用于复杂性肺部疾病的阿米卡星脂质体吸入混悬液
Sr Care Pharm. 2020 Apr 1;35(4):162-170. doi: 10.4140/TCP.n.2020.162.
6
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.硫酸卷曲霉素脂质体吸入混悬液治疗鸟分枝杆菌复合体肺病的研究进展
Drugs. 2019 Apr;79(5):555-562. doi: 10.1007/s40265-019-01095-z.
7
Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Complex Lung Disease in Real-World Settings.现实环境中脂质体阿米卡星吸入治疗难治性复杂肺部疾病的早期不良反应及管理
Infect Drug Resist. 2022 Jul 26;15:4001-4011. doi: 10.2147/IDR.S373783. eCollection 2022.
8
Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease.阿米卡星脂质体吸入混悬液在难治性鸟分枝杆菌复合群肺病的真实世界管理中的应用
Cureus. 2024 Mar 21;16(3):e56622. doi: 10.7759/cureus.56622. eCollection 2024 Mar.
9
Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Complex Pulmonary Disease: A Case Report.难治性复杂肺部疾病中与阿米卡星脂质体吸入混悬液相关的药物性间质性肺疾病的诊断与管理：一例报告
Infect Drug Resist. 2023 Oct 10;16:6629-6634. doi: 10.2147/IDR.S427544. eCollection 2023.
10
Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings.在真实环境中，采用阿米卡星脂质体吸入混悬液治疗对住院和其他医疗资源利用措施的影响：一项回顾性队列研究。
BMC Pulm Med. 2022 Dec 3;22(1):461. doi: 10.1186/s12890-022-02257-8.
引用本文的文献
1
Predictive risk factors of treatment-refractory complex lung disease: a single-center retrospective cohort study.治疗难治性复杂性肺部疾病的预测风险因素：一项单中心回顾性队列研究。
Ther Adv Infect Dis. 2025 Apr 11;12:20499361251331676. doi: 10.1177/20499361251331676. eCollection 2025 Jan-Dec.
2
Amikacin Liposomal Inhalation Suspension for Non-Tuberculous Lung Infection: A Greek Observational Study.阿米卡星脂质体吸入混悬液治疗非结核性肺部感染：一项希腊观察性研究。
Medicina (Kaunas). 2024 Oct 3;60(10):1620. doi: 10.3390/medicina60101620.
3
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.起始治疗 6 个月后，卷曲霉素脂质体吸入混悬液治疗耐多药鸟分枝杆菌复合群肺病的疗效。
BMC Pulm Med. 2024 Sep 10;24(1):442. doi: 10.1186/s12890-024-03261-w.
4
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension.探索接受阿米卡星脂质体吸入混悬液的成人不良事件缓解策略的定性访谈
Pulm Ther. 2024 Sep;10(3):315-330. doi: 10.1007/s41030-024-00263-1. Epub 2024 Jul 16.
5
Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Complex Lung Disease in Real-World Settings.现实环境中脂质体阿米卡星吸入治疗难治性复杂肺部疾病的早期不良反应及管理
Infect Drug Resist. 2022 Jul 26;15:4001-4011. doi: 10.2147/IDR.S373783. eCollection 2022.
6
Laryngitis after inhalation of liposomal amikacin.吸入脂质体阿米卡星后发生的喉炎。
Clin Case Rep. 2022 Feb 20;10(2):e05350. doi: 10.1002/ccr3.5350. eCollection 2022 Feb.
7
Aerosolized Liposomal Amikacin and Laryngeal Injury.雾化脂质体阿米卡星与喉部损伤
Chest. 2021 Sep;160(3):e316-e317. doi: 10.1016/j.chest.2021.05.050.
8
Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues.新型阿米卡星-脱氧胆酸盐疏水盐的首次体内评估为阿米卡星在血液和组织中的分配提供了新见解。
Pharmaceutics. 2021 Jan 10;13(1):85. doi: 10.3390/pharmaceutics13010085.
本文引用的文献
1
Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK.在英国，初级保健人群中非结核分枝杆菌病的风险因素和二级保健利用情况。
Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):117-124. doi: 10.1007/s10096-018-3402-8. Epub 2018 Oct 27.
2
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂（CONVERT）引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
3
British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).英国胸科学会非结核分枝杆菌肺病（NTM-PD）管理指南。
BMJ Open Respir Res. 2017 Oct 19;4(1):e000242. doi: 10.1136/bmjresp-2017-000242. eCollection 2017.
4
Acute Exacerbation in Interstitial Lung Disease.间质性肺疾病的急性加重
Front Med (Lausanne). 2017 Oct 23;4:176. doi: 10.3389/fmed.2017.00176. eCollection 2017.
5
Effectiveness of treatment with nebulized colistin in patients with COPD.雾化多粘菌素治疗慢性阻塞性肺疾病患者的疗效
Int J Chron Obstruct Pulmon Dis. 2017 Oct 5;12:2909-2915. doi: 10.2147/COPD.S138428. eCollection 2017.
6
The risk of mycobacterial infections associated with inhaled corticosteroid use.吸入性皮质类固醇使用相关的分枝杆菌感染风险。
Eur Respir J. 2017 Sep 20;50(3). doi: 10.1183/13993003.00037-2017. Print 2017 Sep.
7
Personalising airway clearance in chronic lung disease.慢性肺病气道廓清的个体化治疗
Eur Respir Rev. 2017 Feb 21;26(143). doi: 10.1183/16000617.0086-2016. Print 2017 Jan.
8
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.脂质体阿米卡星吸入治疗非结核分枝杆菌肺病的随机试验
Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823. doi: 10.1164/rccm.201604-0700OC.
9
Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review.原发性纤毛运动障碍的诊断、监测与治疗：基于最新综述的PCD基金会共识建议
Pediatr Pulmonol. 2016 Feb;51(2):115-32. doi: 10.1002/ppul.23304. Epub 2015 Sep 29.
10
Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.人类非结核分枝杆菌肺部感染的流行病学：综述
Clin Chest Med. 2015 Mar;36(1):13-34. doi: 10.1016/j.ccm.2014.10.002. Epub 2014 Nov 6.
Zotero 插件